Trial Profile
Long-term Study of S-877489 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Shionogi
- 12 Apr 2018 Status changed from active, no longer recruiting to completed.
- 09 Jun 2016 New trial record